ConductScience.org, home

Paper36910362

Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.

Tang X and 3 others. Afr Health Sci, 2022. Cited by 11 papers, by iCite.

Cite this record

ConductScience Library. Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Papers, record 36910362. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36910362

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
PubMed
Journal
Afr Health Sci
PubMed
Year
2022
PubMed
Publication types
Meta-Analysis, Journal Article
PubMed
Citations, by iCite
11
iCite
Relative citation ratio, by iCite
1.02
iCite
Revised in PubMed
2023-03-14
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tang XXue
2Zhang HHuaping
3Wang XXin
4Yang DDan

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Non-alcoholic Fatty Liver DiseaseMajor topic
Humans
Randomized Controlled Trials as Topic
Benzhydryl Compounds
Glucosides
Liver

References32

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
124322742Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review.Hepatobiliary Pancreat Dis Int2013https://conductscience.org/library/papers/24322742PubMed
212111919Quantifying heterogeneity in a meta-analysis.Stat Med2002https://conductscience.org/library/papers/12111919PubMed
311003611Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study.Hepatology2000https://conductscience.org/library/papers/11003611PubMed
420388946Therapy of nonalcoholic fatty liver disease: current status.J Physiol Pharmacol2009https://conductscience.org/library/papers/20388946PubMed
528303724Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.Drug Metab Rev2017https://conductscience.org/library/papers/28303724PubMed
629085205Treatment options for alcoholic and non-alcoholic fatty liver disease: A review.World J Gastroenterol2017https://conductscience.org/library/papers/29085205PubMed
78721797Assessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials1996https://conductscience.org/library/papers/8721797PubMed
833586120Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Diabetes Ther2021https://conductscience.org/library/papers/33586120PubMed
929229391Hepatocyte-specific clusterin overexpression attenuates diet-induced nonalcoholic steatohepatitis.Biochem Biophys Res Commun2018https://conductscience.org/library/papers/29229391PubMed
1030601337Serum fetuin-B level is an independent marker for nonalcoholic fatty liver disease in patients with type 2 diabetes.Eur J Gastroenterol Hepatol2019https://conductscience.org/library/papers/30601337PubMed
1123707905Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.Eur J Pharmacol2013https://conductscience.org/library/papers/23707905PubMed
1227627981Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.Diabetologia2016https://conductscience.org/library/papers/27627981PubMed
1325477264Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.J Hepatol2015https://conductscience.org/library/papers/25477264PubMed
1411730399Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses.Ann Intern Med2001https://conductscience.org/library/papers/11730399PubMed
1524185985NAFLD-the next global epidemic.Nat Rev Gastroenterol Hepatol2013https://conductscience.org/library/papers/24185985PubMed
1618945255Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.Aliment Pharmacol Ther2009https://conductscience.org/library/papers/18945255PubMed
1728953675Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis.Medicine (Baltimore)2017https://conductscience.org/library/papers/28953675PubMed
1814752836Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver.Hepatology2004https://conductscience.org/library/papers/14752836PubMed
1931748838Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes.Curr Diab Rep2019https://conductscience.org/library/papers/31748838PubMed
2015629518The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.J Hepatol2005https://conductscience.org/library/papers/15629518PubMed

See all 32 referencesDownload CSV of references

Cited by9

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.

PMIDTitleJournalYearIn PapersSource
42969364Changes in liver steatosis and liver stiffness following Empagliflozin treatment in patients with MASLD and type 2 diabetes: A single-arm pre-post study.J Diabetes Investig2026https://conductscience.org/library/papers/42969364PubMed
42504019Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis.Endocrinol Diabetes Metab2026https://conductscience.org/library/papers/42504019PubMed
42352264Emerging Therapeutic Perspectives in Obese Patients with MASLD Leading to Compensated Advanced Chronic Liver Disease.Biomolecules2026https://conductscience.org/library/papers/42352264PubMed
42153018Hepatoprotective effects of cinnamaldehyde against high-fat diet-induced liver damage.Avicenna J Phytomed2026https://conductscience.org/library/papers/42153018PubMed
41717349Efficacy of empagliflozin in patients with metabolic dysfunction-associated steatotic liver disease with or without diabetes: a systematic review and meta-analysis of randomized controlled trials.Front Med (Lausanne)2025https://conductscience.org/library/papers/41717349PubMed
41316185Effect of empagliflozin on liver fibrosis and steatosis in patients with type 2 diabetes and non-alcoholic fatty liver disease: a randomized clinical trial.BMC Endocr Disord2025https://conductscience.org/library/papers/41316185PubMed
40589542Metabolic-Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel Therapies.Int J Hepatol2025https://conductscience.org/library/papers/40589542PubMed
36936142Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis.Front Endocrinol (Lausanne)2023https://conductscience.org/library/papers/36936142PubMed
36910355Editorial I: So, who wins? It is still: NCDs 3; Infections 2.Afr Health Sci2022https://conductscience.org/library/papers/36910355PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
GPT2875PubTator's text mininghttps://conductscience.org/library/genes/2875NCBI Gene
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630NCBI Gene
SLC17A526503PubTator's text mininghttps://conductscience.org/library/genes/26503NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36910362

GET https://conductscience.org/api/papers/v1/36910362/references?page=2